DelveInsight’s ‘Facioscapulohumeral Muscular Dystrophy Pipeline Insight 2023’ report provides comprehensive global coverage of available, marketed, and pipeline Facioscapulohumeral Muscular Dystrophy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Facioscapulohumeral Muscular Dystrophy pipeline domain.

Facioscapulohumeral Muscular Dystrophy Overview

Facioscapulohumeral muscular dystrophy is a genetic muscle disorder in which the muscles of the face, shoulder blades, and upper arms are among the most affected. Hamstring and trunk muscles are affected early on but are less well recognized. Other arm and leg muscles are frequently eventually affected in the course of the disease.

Some of the key takeaways from the Facioscapulohumeral Muscular Dystrophy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Facioscapulohumeral Muscular Dystrophy treatment therapies with a considerable amount of success over the years. Facioscapulohumeral Muscular Dystrophy Key players such as – miRecule, Fulcrum Therapeutics, Dyne Therapeutics, Avidity Biosciences, and others, are developing therapies for the Facioscapulohumeral Muscular Dystrophy treatment 
• Facioscapulohumeral Muscular Dystrophy Emerging therapies such as -AOC 1020, Losmapimod, MC-DX4, DYNE-301 , and others are expected to have a significant impact on the Facioscapulohumeral Muscular Dystrophy market in the coming years.
• In June 2022, Fulcrum Therapeutics initiated a randomized, double- blind, placebo-controlled, multi-national trial to evaluate the efficacy and safety of losmapimod for the treatment of FSHD. Patients will be randomized 1:1 to receive either losmapimod, administered orally as a 15 mg tablet twice a day, or placebo, and evaluated over a 48-week treatment period.
• In January 2020, Fulcrum Therapeutics received orphan drug designation for losmapimod, a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor for the treatment of facioscapulohumeral muscular dystrophy (FSHD). In May 2021, US FDA granted Fast Track designation to losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy.

Discover more about the emerging Facioscapulohumeral Muscular Dystrophy drugs @ Facioscapulohumeral Muscular Dystrophy Treatment Drugs

Emerging Facioscapulohumeral Muscular Dystrophy Drugs Under Different Phases of Clinical Development Include: 

• DYNE-301: Dyne Therapeutics
• AOC 1020: Avidity Biosciences
• MC-DX4: miRecule
• Losmapimod: Fulcrum Therapeutics

Facioscapulohumeral Muscular Dystrophy Pipeline Analysis:

The Facioscapulohumeral Muscular Dystrophy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the Facioscapulohumeral Muscular Dystrophy treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Facioscapulohumeral Muscular Dystrophy Treatment.
• Facioscapulohumeral Muscular Dystrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Facioscapulohumeral Muscular Dystrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Facioscapulohumeral Muscular Dystrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Facioscapulohumeral Muscular Dystrophy Market Drivers

• Advancement in the medical technology
• Investigation into the molecular consequences of DUX4 expression
• Demand for effective Facioscapulohumeral Muscular Dystrophy treatment options and novel therapies.

Facioscapulohumeral Muscular Dystrophy Market Barriers

• Lack of approved Facioscapulohumeral Muscular Dystrophy therapies
• Complications involved with Facioscapulohumeral Muscular Dystrophy

Find out more about the Facioscapulohumeral Muscular Dystrophy treatment options in development @ Facioscapulohumeral Muscular Dystrophy Clinical Trials

Scope of Facioscapulohumeral Muscular Dystrophy Pipeline Drug Insight    

• Coverage: Global
• Key Facioscapulohumeral Muscular Dystrophy Companies: miRecule, Fulcrum Therapeutics, Dyne Therapeutics, Avidity Biosciences, and others
• Key Facioscapulohumeral Muscular Dystrophy Therapies: AOC 1020, Losmapimod, MC-DX4, DYNE-301, and others
• Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment: Facioscapulohumeral Muscular Dystrophy current marketed and Facioscapulohumeral Muscular Dystrophy emerging therapies
• Facioscapulohumeral Muscular Dystrophy Market Dynamics:  Facioscapulohumeral Muscular Dystrophy market drivers and Facioscapulohumeral Muscular Dystrophy market barriers 

Table of Contents

1. Introduction

2. Executive Summary

3. Facioscapulohumeral Muscular Dystrophy Overview

4. Facioscapulohumeral Muscular Dystrophy Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Facioscapulohumeral Muscular Dystrophy Therapeutic Assessment

11. Facioscapulohumeral Muscular Dystrophy Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Facioscapulohumeral Muscular Dystrophy Unmet Needs

14. Facioscapulohumeral Muscular Dystrophy Market Drivers and Facioscapulohumeral Muscular Dystrophy Market Barriers

15. Appendix

16. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Navdha Goel
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com